COVID-19 Patients with Respiratory Failure to Be Given NuvOx Pharma's Oxygen Therapeutic in Phase IIa Clinical Trial

July 29, 2020

Jarrod Mosier, MD, associate professor, UArizona Emergency Medicine and Internal Medicine and associate program director of the Critical Care Fellowship at Banner University Medical Center - Tucson, is a principal investigator of the U.S. sites in a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).

Some patients with AHRF can progress to a more severe form of the disease called acute respiratory distress syndrome (ARDS). ARDS, which is associated with lung inflammation leading to low blood oxygenation, is the major cause of death in COVID-19 patients. Evan Unger, MD, president and CEO of NuvOx Pharma, a Tucson-based biotechnology company developing NanO2™ emulsion for oxygen delivery, said, “We had data in several animal models showing that NanO2 restored oxygen levels in conditions of low oxygen caused by ARDS or acute lung injury. We already have data in humans from when NanO2 was tested in subjects with brain cancer and stroke showing safety and evidence of efficacy in both indications. Because of this, we designed a clinical trial to study NanO2 in COVID-19 patients.”

NuvOx Pharma,, has received a “No Objection Letter” from Health Canada to proceed with the Phase IIa clinical trial. Diego Martin, MD, PhD, chairman of radiology at McGill University, Montreal, Canada, principal investigator of the Canadian efforts on the trial, said, “We are excited to collaborate with NuvOx Pharma on this project. I have been collaborating with Dr. Unger to study models of myocardial infarction where we have published evidence that shows NanO2 can act as a cardioprotectant. In addition to ARDS, COVID-19 patients suffer multi-organ damage to the heart, brain, kidneys and other organs. In fact, a large percentage of patients who succumb to COVID-19 also have underlying cardiac disease or cardiovascular risk factors. NanO2 appears to be reversing ischemia-mediated pathways of inflammation and tissue injury in lung, heart and other tissues, which may make it particularly well-suited as a treatment in COVID-19 subjects.”

Dr. Mosier said, “NanO2 will be administered as a sustained IV infusion in the clinical trial. The first phase of the trial is a dose escalation design to determine the best dose, after which additional subjects will be enrolled at that dose as a dose expansion phase. The trial will determine if NanO2 improves clinical outcomes in COVID-19 subjects with acute hypoxic respiratory failure. NanO2 has the potential to transform the care of COVID-19 patients who present with low oxygen saturation.”

#  #  #